News: Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

84.60EUR
24 Oct 2014
Price Change (% chg)

€-0.30 (-0.35%)
Prev Close
€84.90
Open
€84.60
Day's High
€84.89
Day's Low
€84.02
Volume
2,561,457
Avg. Vol
3,148,961
52-wk High
€89.95
52-wk Low
€68.29

Search Stocks
Select another date:

Mon, Oct 20 2014

Actavis, Sanofi among bidders for Omega Pharma: Bloomberg

- Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV [COUCKO.UL], Bloomberg reported, citing people familiar with the matter.

Actavis, Sanofi among bidders for Omega Pharma - Bloomberg

Oct 20 - Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV, Bloomberg reported, citing people familiar with the matter.

Sanofi, Regeneron start Phase 3 trial of dupilumab in eczema

PARIS, Oct 20 - French drugmaker Sanofi and its U.S. partner Regeneron said on Monday they had started a Phase III clinical study of their experimental drug dupilumab in patients with atopic dermatitis.

BRIEF-Ab-Biotics, Sanofi to launch a gastro-pediatric drug in Spain

* Said on Thursday it reached agreement with French Sanofi to launch a gastro-pediatric drug in Spain

Belgium's Galapagos hires Sanofi Europe exec as new CFO

BRUSSELS, Oct 15 - Belgian biotech group Galapagos said on Wednesday that it had hired Bart Filius, vice president of Sanofi Europe, as its new chief financial officer.

Geographic split likely for GSK mature drugs sale: sources

LONDON - GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process.

Geographic split likely for GSK mature drugs sale -sources

LONDON, Oct 14 - GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process.

Sanofi's Rotavirus vaccine enters late-stage trials

PARIS - French drugmaker Sanofi said on Tuesday an investigational vaccine designed by its Shantha Biotechnics unit to protect young children from severe diarrhea had entered late-stage clinical trials in India.

Sanofi's Rotavirus vaccine enters late-stage trials

PARIS, Oct 14 - French drugmaker Sanofi said on Tuesday an investigational vaccine designed by its Shantha Biotechnics unit to protect young children from severe diarrhoea had entered late-stage clinical trials in India.

Sanofi French head Lajoux to leave at end-2014

PARIS - Sanofi's head of France, Christian Lajoux, plans to leave at the end of the year after 21 years with the drug making company, Chief Executive Chris Viehbacher said in a message to staff.

Select another date:
Search Stocks